**Specifications Table**TableSubject area*Pharmacology*More specific subject area*Pharmacotherapy for Cocaine Use Disorder (CUD)*Type of data*Text file, table*How data was acquired*Human laboratory setting. Self-report questionnaires, computerized cognitive testing, heart rate and blood pressure measurements.*Data format*Analyzed*Experimental factors*Within-subject fixed factor of 'dose' (placebo, 40 mg, 80 mg atomoxetine); between-subject factor of 'sex' (male, female)*Experimental features*Double-blind, placebo-controlled, within-subject cross-over design with one pill condition (placebo, 40 mg or 80 mg atomoxetine) on each test day, with washout time between test days. Participants met criteria for cocaine use disorder but were abstinent from cocaine for 1-12 months.*Data source location*West Haven, CT*Data accessibility*Data is not available in a public repository.*

**Value of the data**•There are no pharmacotherapies currently approved for the treatment of CUD. Pharmacotherapies with low abuse potential but cognitive enhancing properties could be effective adjunct therapies for CUD, since poorer cognitive function has been linked with worse clinical outcomes including risk of relapse [@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7].•A norephinephrine transporter inhibitor, atomoxetine, has been proposed as a candidate treatment for CUD, based on its efficacy as a cognitive enhancer in other clinical populations [@bib8], [@bib9] and its impact on addictive processes in preclinical [@bib10], [@bib11], [@bib12], [@bib13], [@bib14] and human laboratory studies [@bib15], [@bib16], [@bib17].•Sex is a potentially important factor which could contribute to individual variability in response to medication [@bib18]. Sex differences have been demonstrated in the etiology, disease course, health consequences and treatment response of CUDs (e.g. [@bib19], [@bib20], [@bib21], [@bib22], [@bib23]), including poorer clinical outcomes for women in trials of medications for CUDs (e.g. disulfiram [@bib24], modafinil [@bib25], naltrexone [@bib26]). There is mixed evidence of sex differences in response to atomoxetine for attention deficit hyperactivity disorder (ADHD) ([@bib27], but see also [@bib28]). Preclinical research indicates greater efficacy for atomoxetine in males than females [@bib29], [@bib30]. Although data specifically testing sex differences in atomoxetine response is limited, convergent evidence underlines the likelihood of sex-sensitive effects of noradrenergic medication for substance use disorders (e.g. [@bib31]).•The sample size in the current data was underpowered to investigate sex differences properly. These preliminary data may be hypothesis-generating for future studies of atomoxetine in men and women with CUD.

1. Data {#s0005}
=======

Data presented are from a secondary analyses of sex differences. Data are subjective drug effects, cardiovascular response, and computerized cognitive task outcomes in abstinent individuals with cocaine use disorder (CUD) who received placebo, 40 mg atomoxetine and 80 mg atomoxetine. The detailed methods and primary dose effects analyses from this dataset are reported elsewhere [@bib1].

Baseline and demographics data are reported in full in [Table 1](#t0005){ref-type="table"}. Data for the effects of atomoxetine by sex on cardiovascular responses, subjective drug responses, mood and cognitive function are reported in [Table 2](#t0010){ref-type="table"}. Briefly, treatment-by-sex interactions on drug-like effects showed more positive (euphoria) and less negative (dysphoria, sedation) subjective effects in women relative to men in response to the medication versus placebo. For mood, treatment-by-sex interactions reflected atomoxetine dose-related decreases in 'fatigue' and 'depression' in men, but increases in women. Furthermore, treatment-by-sex interaction indicated reduced 'tension' at the low-dose (relative to placebo or high-dose) condition, in men but not women. In terms of cognitive function, a treatment-by-sex interaction on Immediate Memory Task (IMT) revealed dose-related improvements (e.g., faster correct responses) in men, but a trend of dose-related decrements in performance in women.Table 1Baseline measures by sex.Table 1**MeasuresSexMale (*N*=29)Female (*N*=10)Statistics (by Sex)***N(%)N(%)Wald(p)***Demographics**Race1.370.242 African American/Black1448.28%770.00%  Not of Hispanic Origin1448.28%770.00%  Hispanic Origin00.00%00.00% European American1551.72%330.00%  Not of Hispanic Origin1448.28%110.00%  Hispanic Origin13.45%220.00%Highest level of completed education**5.340.021** College/University graduate13.45%00.00% Partial college training1034.48%110.00% High School graduate/GED1758.62%660.00% Partial high school13.45%330.00%Marital status1.850.605 Never married1655.17%660.00% Married517.24%110.00% Separated26.90%220.00% Divorced620.69%110.00%Employment status1.420.492 Full-time (35 or more hours per week)517.24%220.00% Unemployed less than one month26.90%220.00% Unemployed greater than one month2275.86%660.00%SexN/AN/A Male29100.00%00.00% Female00.00%10100.00%              *Mean(SD)Mean(SD)F(p)*Age, years40.937.6242.007.360.150.702**Self-reported measures at baseline**CES-D summary score8.957.158.205.630.090.766CTQ Physical Abuse7.794.1910.405.762.350.134 Physical Neglect7.793.169.604.621.910.176 Emotional Abuse8.454.7010.004.270.850.364 Emotional Neglect9.935.4411.224.940.400.530 Sexual Abuse7.004.897.904.770.250.617[^1]Table 2Sex analyses.Table 2**SexStatisticOutcome MeasuresWomen (*N*=10)Men (*N*=29)DoseSexSex by DosePlacebo40 mg80 mgPlacebo40 mg80 mg***F(p)F(p)F(p)MeanSDMeanSDMeanSDMeanSDMeanSDMeanSD***Cardiovascular**  Heart Rate73.539.0578.209.9978.5312.5571.6910.6974.5111.5076.5712.6630.51 (\<0.0001); 40,80ATX\>PLA----  Systolic BP118.6010.15122.5311.89121.5811.29119.9211.07123.1712.65124.0311.9810.45 (\<0.0001); 40,80ATX\>PLA----  Diastolic BP71.808.3072.977.8074.077.8971.038.8672.4511.2373.1710.195.35 (0.005); 80 ATX\>PLA----**Subjective drug effects** *ARCI*  Sedation (PCAG)[⁎](#tbl2fnStar){ref-type="table-fn"}4.833.644.493.164.053.023.132.022.971.883.622.86----4.77 (0.009); M: 80ATX\>PLA,40ATX; W: NS  Dysphoria (LSD)[⁎](#tbl2fnStar){ref-type="table-fn"}3.081.943.331.753.081.622.441.272.641.573.252.15----3.45 (0.033); M: 80ATX\>PLA,40ATX; W: NS  Euphoria (MBG)[⁎](#tbl2fnStar){ref-type="table-fn"}5.184.685.874.626.404.636.314.806.024.735.494.29----3.92 (0.021); M: NS; W: 80ATX\>PLA  Stimulant-Like Effects (A)3.932.484.102.724.282.724.102.584.232.484.032.34------  Intellectual Efficiency and Energy (BG)6.632.876.643.016.783.176.832.286.822.016.422.31------ *DEQ*  Feel Good Factor0.670.930.871.130.620.860.681.061.121.300.881.015.92 (0.003); 40ATX\>PLA, 80ATX----  Negative Factor0.530.890.690.810.610.800.620.710.860.890.780.855.40 (0.005); 40 ATX\>PLA----  Stimulatory Factor0.600.831.191.101.031.170.891.161.221.651.121.099.75 (\<0.0001); 40,80ATX\>PLA----                                **Mood** *POMS*  Anger1.181.391.431.931.731.682.251.652.602.172.432.54------  Depression2.502.002.652.003.152.243.842.553.632.373.812.61--4.28 (0.045); M\>W--  Fatigue[⁎](#tbl2fnStar){ref-type="table-fn"}4.223.113.832.844.882.926.633.116.113.246.173.034.27 (0.015); PLA,80ATX\>40ATX6.67 (0.013); M\>W3.54 (0.030); M: PLA\>40,80ATX; W: 80ATX\>40ATX; M\>W at PLA, 40ATX but not 80ATX  Confusion4.730.885.041.474.701.024.481.254.671.204.641.55------  Tension[⁎](#tbl2fnStar){ref-type="table-fn"}3.831.894.382.254.252.325.592.065.442.225.622.01--8.70 (0.005); M\>W3.24 (0.040); M: PLA\>40ATX; W: NS; M\>W at PLA, 80ATX but not 40ATX  Vigor2.132.192.202.422.702.202.691.642.902.112.972.19------**Cognitive** *IMT*  Discriminability (d\')0.700.520.860.950.730.701.160.821.240.961.290.91------Response Bias (Beta)1.210.361.772.251.160.391.130.481.180.611.090.65------  Mean Correct RT[⁎](#tbl2fnStar){ref-type="table-fn"}537.3575.56556.9663.48540.4155.84544.6784.88520.0986.73530.8390.67----3.84 (0.026); M: PLA\>40ATX; W: NS *RVP*  Discriminability (A\')0.870.050.870.040.880.070.870.110.890.060.890.07------  Response Bias (B\'\')0.770.190.810.180.820.200.850.230.890.120.870.14------  Mean Correct RT520.65103.83520.01126.21565.78183.42442.82110.75420.5287.35410.7478.63------ *SST*  SSRT255.78155.57250.90174.04292.30156.95215.8775.00211.0779.29192.9984.54------  Median Correct RT688.90227.89653.95164.26642.05203.94656.69169.64657.45212.92636.59186.16------  Mean Correct RT742.82242.90721.26186.97698.29218.80735.18222.37724.19256.57684.82197.88------  SD of Correct RT318.79171.65391.27300.21320.29248.84437.87417.17384.95301.41290.72198.74------[^2][^3][^4][^5]

2. Experimental design, materials and methods {#s0010}
=============================================

Methods are described in detail elsewhere [@bib1]. Participants were otherwise healthy individuals (*N*=39) who met diagnostic criteria for cocaine dependence in early remission (i.e., abstinent \>30 days, \<1 year).

In this randomized, double-blind, placebo-controlled, within-subject crossover design participants received 40 mg, 80 mg atomoxetine, and placebo treatment, one pill per day, over three test days. Test days were scheduled approximately 6 days apart. Order of treatment condition (across test days) was randomly assigned and counter-balanced across individuals.

Outcome measures included cardiovascular (heart rate, blood pressure), subjective drug effects (Drug Effects Questionnaire (DEQ) [@bib32]; Addiction Research Center Inventory (ARCI) [@bib33]), mood Profile of Mood States (POMS) [@bib34], and cognitive tasks measuring memory, attention and response inhibition performance (Immediate Memory Task (IMT) [@bib35], [@bib36], [@bib37]; CANTAB Rapid Visual Information Processing (RVP) [@bib38]; CANTAB Stop Signal Task (SST) [@bib39]).

For demographic and baseline data, men and women were compared using analysis of variance (ANOVA) for continuous, or logistic regression for categorical variables. A mixed-effect repeated-measures analysis assessed in JMP (version 11.0) for treatment effect; including a fixed main effect for treatment (placebo, 40 or 80 mg atomoxetine), a random effect for participant, and a between subject factor of sex (men, women) and sex by treatment effect interaction term. When data was collected across multiple time points, all post-pill administration time-points were included in the analyses. To account for possible carryover effects of the medication or learning/test-retest effects across testing days, analyses were re-run including test day (1,2,3) and test day interactions. Findings (i.e., significance level) remained stable with and without test day, therefore data are presented from the simpler analysis excluding day. Bonferroni corrections were applied for the number of outcomes tested within each domain (cardiovascular, subjective drug effect, mood, cognition). Reported data survive Bonferroni corrections unless otherwise stated.
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[^1]: Statistics (F(p)) or Wald (p) as appropriate, are reported. Results reaching the statistical significance at *p*≤0.05 level are considered statistically significant (bold). CES-D: Center for Epidemiologic Studies Depression Scale; CTQ: Childhood Trauma Questionnaire; SD: Standard Deviation.

[^2]: Raw means and standard deviations are reported by sex. ATX: atomoxetine; PLA: Placebo; SD: Standard Deviation; POMS: Profile of Mood States; ARCI: Addiction Research Center Inventory; DEQ: Drug Effects Questionnaire; BP: blood pressure; RT: response time (ms); SSRT: Stop-Signal Reaction-Time; RVP: Rapid Visual Processing; SST: Stop Signal Task; IMT: Immediate Memory Task.

[^3]: Missing data by sex and dose visit: No missing data for women (*N*=10 at each dose visit); Men Placebo visit (5 missing DEQ, ARCI, Physiological; 4 missing SST, RVP; 3 missing IMT); Men 40ATX visit (2 missing RVP, SST, IMT); Men 80ATX visit (3 missing DEQ, ARCI, POMS, Physiological, Cognitive).

[^4]: Statistics that did not reach at least significance level of *p*\<0.05 are not reported (indicated by \'-\')

[^5]: Indicates dose by sex interaction effect (uncorrected *p*\<0.05).
